Trial Profile

A placebo-controlled Phase 2 clinical study evaluating EVX-101, as adjunctive therapy, in patients with obsessive-compulsive disorder (OCD) with inadequate response to first-line selective serotonin-reuptake inhibitors (SSRIs).

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 24 Feb 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

09 Feb 2026 According to the Evecxia Media Release, the company plans to start this first Phase 2 trial of lead candidate EVX-101 in obsessive-compulsive disorder (OCD) patients in 2H 2026
06 Nov 2025 New trial record
22 Sep 2025 According to the Evecxia Media Release, company plans to commence this study in 1H 2026

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com